免费获得国外相关药品，最快 1 个工作日回馈药物信息
出境医 / 临床实验 / Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease (FAVOR4-QVAS)
Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease (FAVOR4-QVAS)
Study Description
Brief Summary:
This is a multicenter, prospective, randomized, blinded, controlled clinical study in patients with planned primary valvular surgery and comorbid coronary artery lesions with diameter stenosis of ≥ 50%, to compare the effectiveness of an Quantitative Flow Ratio (QFR)-guided revascularization strategy and a coronary angiography (CAG)-guided revascularization strategy in preventing the composite outcome (including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, new renal failure requiring dialysis) within 30 days after surgery. The study hypothesis is that the QFR-guided strategy can reduce the incidence of the composite outcome within 30 days after surgery, as compared with the CAG-guided strategy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Primary Valvular Heart Disease With Comorbid Coronary Artery Disease Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease | Device: QFR-guided strategy Other: CAG-guided strategy | Not Applicable |
Detailed Description:
It is planned to enroll 792 subjects aged ≥18 years, with no gender restriction, who plan to undergo elective open-heart valvular surgery due to primary valvular heart disease, with comorbid coronary artery lesions defined as diameter stenosis of ≥ 50% (visual estimation) that are diagnosed by CAG before the surgery.
QFR group: Calculate the QFR values of all target coronary arteries (anterior descending branch, circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm in diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior descending branch and posterior branch of left ventricle) with lesions with diameter stenosis of ≥ 50% (visual estimation) suited for CABG revascularization. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
CAG group (control group): All target coronary arteries (anterior descending branch, circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm in diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior descending branch and posterior branch of left ventricle) with lesions with diameter stenosis of ≥ 50% (visual estimation) suited for CABG revascularization will undergo simultaneous CABG revascularization.
Intervention duration: The assessments will be performed after randomization and before the surgery to guide the surgery.
No planned interim analysis.
Study Design
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 792 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | A Multicenter, Prospective, Randomized, Blind, Controlled Clinical Study to Compare the Efficacy of Quantitative Flow Ratio Guided and Coronary Angiography Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease |
| Actual Study Start Date : | August 4, 2019 |
| Estimated Primary Completion Date : | September 2022 |
| Estimated Study Completion Date : | December 2025 |
Arms and Interventions
| Arm | Intervention/treatment |
|---|---|
| Experimental: QFR group |
Device: QFR-guided strategy
In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
|
| Active Comparator: CAG group |
Other: CAG-guided strategy
In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
|
Outcome Measures
Primary Outcome Measures :
- The incidence of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization and new renal failure requiring dialysis [ Time Frame: within 30 days after surgery ]Compare the incidence of composite outcome between two groups.
Secondary Outcome Measures :
- The time from randomization to first occurrence of any of composite outcome [ Time Frame: within 1 year after surgery ]The time from randomization to first occurrence of any of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, hospitalization or urgent visits for unstable angina pectoris and hospitalization or urgent visits for heart failure
- The incidence of graft failure (stenosis ≥ 50% or occlusion occurred in grafts or distal anastomosis) [ Time Frame: at 1 year after surgery ]
- The time from randomization to first occurrence of any of composite outcome [ Time Frame: within 3 years after surgery ]The time from randomization to first occurrence of any of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, hospitalization or urgent visits for unstable angina pectoris and hospitalization or urgent visits for heart failure
- The incidence of graft failure (stenosis ≥ 50% or occlusion occurred in grafts or distal anastomosis) [ Time Frame: at 3 years after surgery ]
Other Outcome Measures:
- The number of grafts per person (counted as distal anastomosis) [ Time Frame: at Day 0 ]
- The total circulatory time during the surgery (minutes) [ Time Frame: at Day 0 ]
- The total cross-clamp time during the surgery (minutes) [ Time Frame: at Day 0 ]
- The total units of erythrocyte transfusion during and after the surgery till discharge [ Time Frame: from Day 0 to discharge day ]
- The number of days from surgery day to discharge day [ Time Frame: from Day 0 to discharge day ]
- Change from baseline in the Canadian Cardiac Society (CCS) anginal status score (0-4) [ Time Frame: at 1 year after surgery ]
- Change from baseline in the CCS anginal status score (0-4) [ Time Frame: at 3 years after surgery ]
- Change from baseline in the New York Heart Association (NYHA) score (1-4) [ Time Frame: at 1 year after surgery ]
- Change from baseline in the NYHA score (1-4) [ Time Frame: at 3 years after surgery ]
Eligibility Criteria
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Voluntarily participate in the trial and provide the informed consent form;
- Male or female patients aged ≥ 18 years;
- Planned to undergo elective on-pump valve surgery due to primary mitral and/or aortic valvular heart disease (such as rheumatic, degenerative, infective, congenital valvular heart disease, etc.);
- At least one target coronary arteries (anterior descending branch, circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm in diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior descending branch and posterior branch of left ventricle) with preoperative diameter stenosis of ≥ 50% by coronary angiography (visual estimation, subject to written coronary angiography report) and suited for CABG revascularization.
Exclusion Criteria:
- History of heart surgery;
- Planned second-stage PCI or CABG revascularization;
- Secondary valvular heart disease (ischemia, cardiomyopathy);
- Planned valve intervention surgery through the catheter;
- Subjects that were evaluated to have cardiogenic shock or other critical conditions that were not appropriate for the trial by study physician;
- QFR calculations cannot be carried out from preoperative coronary angiography data (such as poor projection position, inability to detect vascular boundaries, poor contrast agent filling, excessive overlap or severely distorted of vessel lesion sections, lesion involved in myocardial bridge, or lesion site within 3 mm from the ostium of the main coronary artery);
- The target coronary arteries were evaluated to be not suitable for CABG by study physician;
- Life expectancy < 3 years.
Contacts and Locations
Contacts
| Contact: Yunpeng Zhu, MD. | +8613816819346 | Zyp12220@rjh.com.cn |
Locations
| China, Henan | |
| Fuwai Central China Cardiovascular Hospital | Recruiting |
| Zhengzhou, Henan, China | |
| Contact: Junlong Hu, MD. dr_hu@henu.edu.cn | |
| Principal Investigator: Zhaoyun Cheng, MD. | |
| Sub-Investigator: Junlong Hu, MD. | |
| China, Hunan | |
| The Second XiangYa Hospital of Central South University | Recruiting |
| Changsha, Hunan, China | |
| Contact: Yuan Zhao, MD. drzhaoyuan@163.com | |
| Principal Investigator: Xinmin Zhou, MD. | |
| Principal Investigator: Yuan Zhao, MD. | |
| Sub-Investigator: Kang Zhou, MD. | |
| China, Shanghai | |
| Ruijin Hospital Shanghai Jiao Tong University School of Medicine | Recruiting |
| Shanghai, Shanghai, China, 200025 | |
| Contact: Yunpeng Zhu, MD. +8613816819346 Zyp12220@rjh.com.cn | |
| Principal Investigator: Qiang Zhao, MD. | |
| Principal Investigator: Yunpeng Zhu, MD. | |
| Sub-Investigator: Jiaxi Zhu, MD. | |
| Sub-Investigator: Yiwei Xu, MD. | |
| Changhai Hospital of Shanghai | Recruiting |
| Shanghai, Shanghai, China | |
| Contact: Qing Xue, MD. xq9911310@163.com | |
| Principal Investigator: Zhiyun Xu, MD. | |
| Principal Investigator: Lin Han, MD. | |
| Sub-Investigator: Qing Xue, MD. | |
| Shanghai Chest Hospital | Recruiting |
| Shanghai, Shanghai, China | |
| Contact: Busheng Zhang, MD. albmu@sina.cn | |
| Principal Investigator: Dan Zhu, MD. | |
| Sub-Investigator: Busheng Zhang, MD. | |
Sponsors and Collaborators
Ruijin Hospital
Med-X Research Institute, Shanghai Jiao Tong University
Investigators
| Principal Investigator: | Qiang Zhao, MD. | Ruijin Hospital | |
| Principal Investigator: | Shengxian Tu, PhD. | Med-X Research Institute, Shanghai Jiao Tong University | |
| Study Director: | Yunpeng Zhu, MD. | Ruijin Hospital |
| Tracking Information | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date ICMJE | June 5, 2019 | |||||||||
| First Posted Date ICMJE | June 6, 2019 | |||||||||
| Last Update Posted Date | December 29, 2020 | |||||||||
| Actual Study Start Date ICMJE | August 4, 2019 | |||||||||
| Estimated Primary Completion Date | September 2022 (Final data collection date for primary outcome measure) | |||||||||
| Current Primary Outcome Measures ICMJE |
The incidence of composite outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization and new renal failure requiring dialysis [ Time Frame: within 30 days after surgery ] Compare the incidence of composite outcome between two groups.
|
|||||||||
| Original Primary Outcome Measures ICMJE | Same as current | |||||||||
| Change History | ||||||||||
| Current Secondary Outcome Measures ICMJE |
|
|||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | |||||||||
| Current Other Pre-specified Outcome Measures |
|
|||||||||
| Original Other Pre-specified Outcome Measures | Same as current | |||||||||
| Descriptive Information | ||||||||||
| Brief Title ICMJE | Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease | |||||||||
| Official Title ICMJE | A Multicenter, Prospective, Randomized, Blind, Controlled Clinical Study to Compare the Efficacy of Quantitative Flow Ratio Guided and Coronary Angiography Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease | |||||||||
| Brief Summary | This is a multicenter, prospective, randomized, blinded, controlled clinical study in patients with planned primary valvular surgery and comorbid coronary artery lesions with diameter stenosis of ≥ 50%, to compare the effectiveness of an Quantitative Flow Ratio (QFR)-guided revascularization strategy and a coronary angiography (CAG)-guided revascularization strategy in preventing the composite outcome (including all-cause death, non-fatal myocardial infarction, non-fatal stroke, unplanned coronary revascularization, new renal failure requiring dialysis) within 30 days after surgery. The study hypothesis is that the QFR-guided strategy can reduce the incidence of the composite outcome within 30 days after surgery, as compared with the CAG-guided strategy. | |||||||||
| Detailed Description |
It is planned to enroll 792 subjects aged ≥18 years, with no gender restriction, who plan to undergo elective open-heart valvular surgery due to primary valvular heart disease, with comorbid coronary artery lesions defined as diameter stenosis of ≥ 50% (visual estimation) that are diagnosed by CAG before the surgery. QFR group: Calculate the QFR values of all target coronary arteries (anterior descending branch, circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm in diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior descending branch and posterior branch of left ventricle) with lesions with diameter stenosis of ≥ 50% (visual estimation) suited for CABG revascularization. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out. CAG group (control group): All target coronary arteries (anterior descending branch, circumflex branch, main right coronary artery or its primary branches with ≥ 1.5 mm in diameter, such as diagonal branch, intermediate branch, obtuse marginal branch, posterior descending branch and posterior branch of left ventricle) with lesions with diameter stenosis of ≥ 50% (visual estimation) suited for CABG revascularization will undergo simultaneous CABG revascularization. Intervention duration: The assessments will be performed after randomization and before the surgery to guide the surgery. No planned interim analysis. |
|||||||||
| Study Type ICMJE | Interventional | |||||||||
| Study Phase ICMJE | Not Applicable | |||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
|||||||||
| Condition ICMJE |
|
|||||||||
| Intervention ICMJE |
|
|||||||||
| Study Arms ICMJE |
|
|||||||||
| Publications * | Not Provided | |||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
| Recruitment Information | ||||||||||
| Recruitment Status ICMJE | Recruiting | |||||||||
| Estimated Enrollment ICMJE |
792 | |||||||||
| Original Estimated Enrollment ICMJE | Same as current | |||||||||
| Estimated Study Completion Date ICMJE | December 2025 | |||||||||
| Estimated Primary Completion Date | September 2022 (Final data collection date for primary outcome measure) | |||||||||
| Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
|||||||||
| Sex/Gender ICMJE |
|
|||||||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||||||||
| Accepts Healthy Volunteers ICMJE | No | |||||||||
| Contacts ICMJE |
|
|||||||||
| Listed Location Countries ICMJE | China | |||||||||
| Removed Location Countries | ||||||||||
| Administrative Information | ||||||||||
| NCT Number ICMJE | NCT03977129 | |||||||||
| Other Study ID Numbers ICMJE | 2018CR001 | |||||||||
| Has Data Monitoring Committee | No | |||||||||
| U.S. FDA-regulated Product |
|
|||||||||
| IPD Sharing Statement ICMJE |
|
|||||||||
| Responsible Party | Qiang Zhao,MD, Ruijin Hospital | |||||||||
| Study Sponsor ICMJE | Ruijin Hospital | |||||||||
| Collaborators ICMJE | Med-X Research Institute, Shanghai Jiao Tong University | |||||||||
| Investigators ICMJE |
|
|||||||||
| PRS Account | Ruijin Hospital | |||||||||
| Verification Date | December 2020 | |||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
||||||||||
